Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

被引：218

作者：

Kerr, K. M. ^{[1
,2
]}

Bubendorf, L. ^{[3
]}

Edelman, M. J. ^{[4
]}

Marchetti, A. ^{[5
]}

Mok, T. ^{[6
]}

Novello, S. ^{[7
]}

O'Byrne, K. ^{[8
,9
]}

Stahel, R. ^{[10
]}

Peters, S. ^{[11
]}

Felip, E. ^{[12
]}

机构：

[1] Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland

[2] Aberdeen Univ Med Sch, Aberdeen, Scotland

[3] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland

[4] Univ New Mexico Canc Ctr, Albuquerque, NM USA

[5] Univ Fdn, Ctr Predict Mol Med, Ctr Excellence Ageing, Chieti, Italy

[6] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

[7] Univ Turin, Azienda Osped Univ San Luigi Orbassano, Dept Oncol, Thorac Oncol Unit, I-10124 Turin, Italy

[8] Trinity Coll Dublin, Dublin, Ireland

[9] Queensland Univ Technol, Brisbane, Qld 4001, Australia

[10] Univ Zurich Hosp, Clin Oncol, CH-8091 Zurich, Switzerland

[11] CHU Vaudois, Dept Oncol, Lausanne, Switzerland

[12] Vall dHebron Univ Hosp, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 09期

关键词：

ESMO; consensus; non-small-cell lung cancer; pathology; molecular testing; recommendations; MESSENGER-RNA EXPRESSION; IN-SITU HYBRIDIZATION; EXTERNAL QUALITY ASSESSMENT; FACTOR RECEPTOR MUTATIONS; ALK GENE REARRANGEMENTS; EML4-ALK FUSION GENE; PHASE-III TRIAL; BRONCHIAL BIOPSY; INTERNATIONAL-ASSOCIATION; HISTOLOGICAL CLASSIFICATION;

D O I：

10.1093/annonc/mdu145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.

引用

页码：1681 / 1690

页数：10

共 50 条

[21] Molecular imaging of hypoxia in non-small-cell lung cancer [J].

Yip, Connie ;

Blower, Philip J. ;

Goh, Vicky ;

Landau, David B. ;

Cook, Gary J. R. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (06) :956-976

[22] Consensus for HER2 alterations testing in non-small-cell lung cancer [J].

Ren, S. ;

Wang, J. ;

Ying, J. ;

Mitsudomi, T. ;

Lee, D. H. ;

Wang, Z. ;

Chu, Q. ;

Mack, P. C. ;

Cheng, Y. ;

Duan, J. ;

Fan, Y. ;

Han, B. ;

Hui, Z. ;

Liu, A. ;

Liu, J. ;

Lu, Y. ;

Ma, Z. ;

Shi, M. ;

Shu, Y. ;

Song, Q. ;

Song, X. ;

Song, Y. ;

Wang, C. ;

Wang, X. ;

Wang, Z. ;

Xu, Y. ;

Yao, Y. ;

Zhang, L. ;

Zhao, M. ;

Zhu, B. ;

Zhang, J. ;

Zhou, C. ;

Hirsch, F. R. .

ESMO OPEN, 2022, 7 (01)

[23] Molecular testing in non-small cell lung cancer: A consensus recommendation [J].

Lai, Gillianne Geet Yi ;

Cheng, Xin Min ;

Ang, Yvonne Li'en ;

Chua, Kevin Lee Min ;

Samol, Jens ;

Soo, Ross ;

Tan, Daniel Shao Weng ;

Lim, Tony Kiat Hon ;

Lim, Darren Wan Teck .

ANNALS ACADEMY OF MEDICINE SINGAPORE, 2023, 52 (07) :364-373

[24] Second-Line Therapy for Non-Small-Cell Lung Cancer [J].

Arango, Belisario A. ;

Castrellon, Aurelio B. ;

Santos, Edgardo S. ;

Raez, Luis E. .

CLINICAL LUNG CANCER, 2009, 10 (02) :91-98

[25] Gefitinib for non-small-cell lung cancer treatment [J].

D'Incecco, Armida ;

Cappuzzo, Federico .

EXPERT OPINION ON DRUG SAFETY, 2011, 10 (06) :987-996

[26] Gefitinib for the treatment of non-small-cell lung cancer [J].

Hida, Toyoaki ;

Ogawa, Shizu ;

Park, Jang Chul ;

Park, Ji Young ;

Shimizu, Junichi ;

Horio, Yoshitsugu ;

Yoshida, Kimihide .

EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (01) :17-35

[27] Second-line erlotinib for non-small-cell lung cancer [J].

Lorusso, Vito ;

Cinieri, Saverio .

LANCET ONCOLOGY, 2012, 13 (04) :E141-E142

[28] Maintenance chemotherapy for non-small-cell lung cancer [J].

Kim, Young Hak ;

Mishima, Michiaki .

CANCER TREATMENT REVIEWS, 2011, 37 (07) :505-510

[29] Personalized medicine for non-small-cell lung cancer [J].

Mok, Tony S. ;

Zhou, Qing ;

Leung, Linda ;

Loong, Herbert H. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) :1601-1611

[30] Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group [J].

Chang, Sunhee ;

Shim, Hyo Sup ;

Kim, Tae Jung ;

Choi, Yoon-La ;

Kim, Wan Seop ;

Shin, Dong Hoon ;

Kim, Lucia ;

Park, Heae Surng ;

Lee, Geon Kook ;

Lee, Chang Hun .

JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2021, 55 (03) :181-191

← 1 2 3 4 5 →